Hemovigilance in the United States of America.
Although hemovigilance is not a word used commonly in the United States, the concept of monitoring morbidity associated with blood transfusion is accepted widely. Currently, quality management focuses on error avoidance rather than error detection in both the "manufacturing" and "clinical" aspects of blood banking. "Manufacturing" is regulated predominantly by current Good Manufacturing Practices while clinical transfusion medicine follows clinical practice guidelines. There are multiple overlapping mechanisms for quality assurance and error reporting among governmental, professional, and non-profit regulatory agencies. The strategies of each stress the on-going need for a systems approaches to preventing errors.
Menitove
J E
JE
Community Blood Center, Kansas City, MO 64111, USA. JEM@CBCKC.ORG
D000068:Accreditation; D001771:Blood Banks / Q000458:organization & administration* / Q000592:standards / Q000706:statistics & numerical data; D001803:Blood Transfusion / Q000592:standards* / Q000706:statistics & numerical data; D002487:Centers for Disease Control and Prevention, U.S.; D014487:Centers for Medicare and Medicaid Services, U.S.; D003245:Consensus Statements as Topic; D017408:Guidelines as Topic; D006739:Hospital Administration; D006801:Humans; D007591:Joint Commission on Accreditation of Healthcare Organizations; D008485:Medical Audit; D009316:National Institutes of Health (U.S.); D011643:Publishing; D011785:Quality Assurance, Health Care / Q000458:organization & administration* / Q000592:standards / Q000706:statistics & numerical data; D018511:Systems Integration; D065227:Transfusion Reaction; D014481:United States; D014486:United States Food and Drug Administration